Angiotensin-Converting Enzyme Inhibitors, Asthma, and Cough: Relighting the Torch
| Autor: | Akio Niimi, Woo-Jung Song |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Epidemiology
AHR Airway hyperresponsiveness Airway hyperresponsiveness Angiotensin-Converting Enzyme Inhibitors COPD Chronic obstructive pulmonary disease BMI Body mass index law.invention HR Hazard ratio NNT Number needed to treat law medicine Immunology and Allergy Humans BTS British Thoracic Society treatment step Asthma ARB Angiotensin-II receptor blocker Torch biology ICS Inhaled corticosteroid business.industry Angiotensin-converting enzyme medicine.disease ACEI Angiotensin converting enzyme inhibitor Cough Immunology Hypertension biology.protein Original Article business Angiotensin converting enzyme |
| Zdroj: | The Journal of Allergy and Clinical Immunology. in Practice |
| ISSN: | 2213-2201 |
| Popis: | Background Angiotensin converting enzyme inhibitor (ACEI) intolerance commonly occurs, requiring switching to an angiotensin-II receptor blocker (ARB). Angiotensin converting enzyme inhibitor intolerance may be mediated by bradykinin, potentially affecting airway hyperresponsiveness. Objective To assess the risk for switching to ARBs in asthma. Methods We conducted a new-user cohort study of ACEI initiators identified from electronic health records from the UK Clinical Practice Research Datalink. The risk for switching to ARBs in people with asthma or chronic obstructive pulmonary disease and the general population was compared. Adjusted hazard ratios (HRs) were calculated using Cox regression, stratified by British Thoracic Society (BTS) treatment step and ACEI type. Results Of 642,336 new users of ACEI, 6.4% had active asthma. The hazard of switching to ARB was greater in people with asthma (HR = 1.16; 95% confidence interval [CI], 1.14-1.18; P ≤ .001) and highest in those at BTS step 3 or greater (HR = 1.35, 95% CI, 1.32-1.39; and HR = 1.18, 95% CI, 1.15-1.22, P ≤ .001 for patients aged ≥60 and |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|